Recent Updates
Recently added Catalysts
HSCS Positive Sentiment Score: 75/100

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Key Takeaway: HeartSciences, also known as Heart Test Laboratories, will participate in the 2024 Maxim Healthcare Virtual Summit from October 15 to 17, 2024. CEO Andrew Simpson is set to engage in a fireside chat with analyst Allen Klee on October 17th. The company focuses on advancing ECG technology through AI to enhance cardiac disease detection and improve clinical care pathways. HeartSciences is also working on its first product candidate, the MyoVista® wavECG™, aimed at providing diagnostic information while maintaining conventional ECG capabilities.

Market Sentiment Analysis

POSITIVE FACTORS

  • HeartSciences' participation in the 2024 Maxim Healthcare Virtual Summit highlights its industry engagement.
  • The company uses AI-powered technology to enhance ECGs, improving detection of heart disease.
  • CEO Andrew Simpson's involvement in a fireside chat may raise awareness and interest in the company's innovations.

Full Press Release Details

Southlake, TX, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced today that Company CEO Andrew Simpson has been invited to participate in the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC and hosted by M-Vest, from Tuesday October 15 to Thursday October 17, 2024.
Mr. Simpson is scheduled to participate in a fireside chat with analyst Allen Klee at 10:30 a.m. Eastern Time on Thursday, October 17th.
Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform. Working with clinical experts, HeartSciences ensures that all solutions are designed to work within existing clinical care pathways, making it easier for clinicians to use AI-ECG technology to improve their patient's care and lead to better outcomes. HeartSciences' first product candidate for FDA clearance, the MyoVista® wavECG™, or the MyoVista®, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista® also provides conventional ECG information in the same test.
For more information, please visit: https://www.heartsciences.com. X: @HeartSciences.
+1-737-414-9213 (US)

Tags

Heart Test Laboratories

Frequently Asked Questions

What does HeartSciences focus on?

HeartSciences specializes in AI-powered medical technology to enhance ECGs for early heart disease detection.

Who is participating in the 2024 Maxim Healthcare Virtual Summit?

CEO Andrew Simpson of HeartSciences is participating in the summit.

What is the MyoVista® wavECG™?

The MyoVista® is a resting 12-lead ECG that provides diagnostic information on cardiac dysfunction.

When is the fireside chat scheduled?

The fireside chat with Andrew Simpson is on October 17th at 10:30 a.m. ET.

How does HeartSciences support clinicians?

HeartSciences designs AI-ECG solutions to integrate seamlessly into existing clinical care pathways.

Last updated: Oct 14, 2024